2022
Acceptability and Feasibility of Online, Asynchronous Photovoice with Key Populations and People Living with HIV
Earnshaw V, Cox J, Wong P, Saifi R, Walters S, Azwa I, Omar S, Collier Z, Hassan A, Lim S, Wickersham J, Haddad M, Kamarulzaman A, Altice F. Acceptability and Feasibility of Online, Asynchronous Photovoice with Key Populations and People Living with HIV. AIDS And Behavior 2022, 27: 2055-2069. PMID: 36463390, PMCID: PMC9734619, DOI: 10.1007/s10461-022-03938-5.Peer-Reviewed Original Research
2019
Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study
Shrestha R, Altice FL, Sibilio B, Ssenyonjo J, Copenhaver MM. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. Contemporary Clinical Trials 2019, 82: 77-84. PMID: 31229618, PMCID: PMC6639056, DOI: 10.1016/j.cct.2019.06.012.Peer-Reviewed Original ResearchConceptsBio-behavioral interventionHIV risk reductionOpioid-dependent peopleMethadone maintenance programPrEP adherenceHIV transmission risk reductionFirst prospective trialPre-exposure prophylaxisHIV prevention strategiesOngoing drug useRisk reductionBehavioral skills modelProspective trialSecondary outcomesPrimary outcomeRisk reduction outcomesHIV riskWeek 20Prevention strategiesUnmet needDrug useHybrid type IBio-behavioral approachProcess evaluationAdherence
2018
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia
Bazazi AR, Wickersham JA, Wegman MP, Culbert GJ, Pillai V, Shrestha R, Al-Darraji H, Copenhaver MM, Kamarulzaman A, Altice FL. Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. Contemporary Clinical Trials 2017, 59: 1-12. PMID: 28479216, PMCID: PMC5557499, DOI: 10.1016/j.cct.2017.05.006.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyHIV transmission risk behaviorsMaintenance therapyTransmission risk behaviorsEvidence-based behavioral interventionsOpioid dependencePoor HIV treatment outcomesRisk behaviorsBehavioral interventionsHIV treatment outcomesProspective clinical trialsEvidence-based treatmentsHealth-related outcomesOpioid useTreatment receiptClinical trialsTreatment outcomesIncarcerated peopleTherapyStudy participantsFactorial trialHIVTrialsInterventionOutcomes
2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentPlacebo-controlled trialXR-NTXAgonist treatmentOpioid dependenceTreatment outcomesPoor HIV treatment outcomesOpioid treatment outcomesOpioid-dependent prisonersExtended-release naltrexoneHIV treatment outcomesHIV transmission riskEvidence-based treatmentsCriminal justice settingsEarly acceptabilityStudy medicationFirst injectionStudy acceptabilityHIVTotal referralsJail detaineesCommunity settingsTransmission riskDrug relapseHigh internal validity
2013
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialHIV treatment outcomesTreatment outcomesCriminal justice system (CJS) populationsPoor antiretroviral therapy (ART) adherenceAlcohol useExtended-release naltrexoneAntiretroviral therapy adherenceMedication-assisted therapyPrevention of relapseAlcohol use disorderSexual risk-taking behaviorsAlcohol-dependent personsXR-NTXHigh morbidityTherapy adherenceAlcohol relapseHigh prevalenceStudy participationEligibility criteriaUse disordersHIVRelapseHazardous drinkingNaltrexone